Cas13d-mediated viral RNA degradation leads to potent antiviral control against both positive and negative sense RNA viruses

Respiratory viral infections continue to pose a substantial global health challenge, with a pressing need for effective treatment options. The rapid mutation rate of RNA viruses presents a significant risk of escape from existing treatments. Here, we harness the rapid adaptability and high sequence specificity of the RNA-targeting CRISPR-Cas13 nuclease technology to target and cleave the genome of different RNA viruses, disrupting replication and impairing propagation. We identified potent CRISPR-RfxCas13d/crRNA (Cas13d/crRNA) combinations that can efficiently restrict viral replication in both pre- and post-viral exposure treatment settings. In vitro treatment with lipid nanoparticles (LNPs) co-encapsulating Cas13d mRNA and crRNAs targeting coding and non-coding regions of positive-sense (+) RNA coronaviruses including SARS-CoV-2 effectively inhibited viral replication. In addition, both pre- and post-viral exposure treatments with the LNP-Cas13d/crRNA against the negative-sense (−) RNA Nipah virus resulted in 99% restriction of this highly pathogenic virus. Hence, the Cas13d/crRNA antiviral method holds promise as a potential therapeutic approach against severe viral infections caused by both (+) and (−) RNA viruses. Furthermore, the multi-locus targeting of viruses by Cas13d could offer a possibility to prevent virus breakthrough and increase the therapeutic arsenal against many emerging RNA viruses in the future.

Authors

Institutions

Publication Details

Journal
Molecular Therapy — Nucleic Acids
Published
2026-11-13
DOI
https://doi.org/10.1016/j.omtn.2026.103122
Primary Topic
CRISPR and Genetic Engineering
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cas13d-mediated viral RNA degradation leads to potent antiviral control against both positive and negative sense RNA viruses

Ulrich Kalinke, Martin Kohn, Branka Horvat, Matthias Bruhn et al.
4 links
Molecular Therapy — Nucleic Acids
CRISPR and Genetic Engineering
article

Cas13d-mediated viral RNA degradation leads to potent antiviral control against both positive and negative sense RNA viruses

Ulrich Kalinke, Martin Kohn, Branka Horvat, Matthias Bruhn, Pimpan Sujariyakul, Simon Alexander Krooss, Lucia Amurri, Jens Bohne, Andreas Pavlou, Sebastian Hook, Heiner Wedemeyer, Vanessa Hamann, Marie Ruhe, Michael Ott, Maureen Obara, Mathieu Iampietro, Anna Carolina Henkel
article en

Abstract

Respiratory viral infections continue to pose a substantial global health challenge, with a pressing need for effective treatment options. The rapid mutation rate of RNA viruses presents a significant risk of escape from existing treatments. Here, we harness the rapid adaptability and high sequence specificity of the RNA-targeting CRISPR-Cas13 nuclease technology to target and cleave the genome of different RNA viruses, disrupting replication and impairing propagation. We identified potent CRISPR-RfxCas13d/crRNA (Cas13d/crRNA) combinations that can efficiently restrict viral replication in both pre- and post-viral exposure treatment settings. In vitro treatment with lipid nanoparticles (LNPs) co-encapsulating Cas13d mRNA and crRNAs targeting coding and non-coding regions of positive-sense (+) RNA coronaviruses including SARS-CoV-2 effectively inhibited viral replication. In addition, both pre- and post-viral exposure treatments with the LNP-Cas13d/crRNA against the negative-sense (−) RNA Nipah virus resulted in 99% restriction of this highly pathogenic virus. Hence, the Cas13d/crRNA antiviral method holds promise as a potential therapeutic approach against severe viral infections caused by both (+) and (−) RNA viruses. Furthermore, the multi-locus targeting of viruses by Cas13d could offer a possibility to prevent virus breakthrough and increase the therapeutic arsenal against many emerging RNA viruses in the future.

Molecular Therapy — Nucleic AcidsVol. 37(4)
Université Claude Bernard Lyon 1 (FR), École Normale Supérieure de Lyon (FR), Centre National de la Recherche Scientifique (FR), Inserm (FR), Renji Hospital (CN), Medizinische Hochschule Hannover (DE), Helmholtz Centre for Infection Research (DE), Centre for Individualised Infection Medicine (DE), Center for Experimental and Clinical Infection Research (DE)
Volkswagen Foundation, Institut National de la Santé et de la Recherche Médicale, Medizinischen Hochschule Hannover
Good health and well-being
CRISPR and Genetic Engineering
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon